<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00448760</url>
  </required_header>
  <id_info>
    <org_study_id>20040006</org_study_id>
    <secondary_id>SCCC-2003151</secondary_id>
    <secondary_id>WIRB-20051464</secondary_id>
    <nct_id>NCT00448760</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery</brief_title>
  <official_title>A Nonrandomized Phase II Study: Feasibility and Outcome of Neo Adjuvant Chemotherapy With Oxaliplatin, Fluorodeoxyuridine (FUdR), Taxotere and Leucovorin in the Treatment of Previously Untreated Advanced Esophago-Gastric Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, floxuridine, docetaxel, and
      leucovorin, work in different ways to stop the growth of tumor cells, either by killing the
      cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy)
      may kill more tumor cells. Giving chemotherapy before surgery may make the tumor smaller and
      reduce the amount of normal tissue that needs to be removed.

      PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating
      patients with previously untreated stage II or stage III esophageal cancer that can be
      removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine whether neoadjuvant chemotherapy comprising oxaliplatin, floxuridine,
           docetaxel, and leucovorin calcium improves the rate of pathologic complete response in
           patients with previously untreated, resectable stage II or III adenocarcinoma of the
           esophagus.

      Secondary

        -  Determine the progression-free and overall survival of patients treated with this
           regimen.

        -  Determine the clinical response rates (complete response and partial response) in
           patients treated with this regimen.

        -  Evaluate thymidylate synthase (TS), mRNA gene expression, TS activity, and TS and mRNA
           sequence, to determine the altered spots as related to drug resistance in these
           patients.

        -  Evaluate the potential for genome-wide gene expression profiling to predict response to
           therapy, recurrence, progression-free survival, overall survival, and drug sensitivity
           and resistance in these patients.

        -  Define the role of 5' untranslated region (5'-UTR) on translation and drug resistance in
           these patients.

        -  Evaluate, by bone marrow aspirate analysis and flow cytometry, the initial presence of
           cancer cells in the marrow, and clearance of these cells after treatment with this
           regimen.

        -  Evaluate the safety of this regimen in these patients.

        -  Assess quality of life of patients during and after treatment with this regimen.

      OUTLINE: This is a nonrandomized, open-label study.

      Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and docetaxel IV over 30
      minutes, floxuridine IV over 24 hours, and leucovorin calcium IV over 24 hours on days 1, 8,
      and 15. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease
      progression or unacceptable toxicity.

      Patients undergo surgery after completion of chemotherapy. Patients who achieve pathologic
      complete response (pCR) receive no further chemotherapy. Patients who have not achieved a pCR
      receive 2 courses of adjuvant chemotherapy (same regimen as the neoadjuvant chemotherapy)
      beginning 3 weeks after surgery.

      Patients undergo blood and tissue collection periodically for correlative studies. Samples
      are analyzed for thymidylate synthase (TS), mRNA gene expression, TS activity, and TS and
      mRNA sequence by bone marrow aspirate, flow cytometry, and quantitative reverse
      transcriptase-polymerase chain reaction.

      Quality of life will be assessed at baseline, after neoadjuvant chemotherapy, after adjuvant
      therapy, and at the first 3-month follow-up visit.

      After completion of study treatment, patients are followed every 3 months for 2 years, every
      6 months for 3 years, and then annually thereafter.

      PROJECTED ACCRUAL: A total of 34 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response</measure>
    <time_frame>8 - 16 weeks</time_frame>
    <description>No evidence of cellular residual cancerous cells as evidenced by tumor tissue samples taken via surgery at the end of neo-adjuvant chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>8 - 16 weeks</time_frame>
    <description>Overall response = Complete response (CR) + Partial Response (PR). Evaluated via endoscopic ultrasounds, PET and CT scans of the chest:
Complete Response (CR) applies to participants complete disappearance of all measurable and evaluable disease. No new lesion. No disease related symptoms. No evidence of non-evaluable disease, including tumor markers and other laboratory values.
Partial Response (PR) applies to participants with at least 50 percent reduction in the sum of the products of bi-dimensional perpendicular diameters of all measurable lesions. No progression of evaluable disease. No new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression-free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant + Adjuvant Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Intravenously, 25 mg/m2, over 30 minutes, 2 cycles</description>
    <arm_group_label>Neoadjuvant + Adjuvant Chemotherapy</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Floxuridine</intervention_name>
    <description>Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles</description>
    <arm_group_label>Neoadjuvant + Adjuvant Chemotherapy</arm_group_label>
    <other_name>FUdR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles</description>
    <arm_group_label>Neoadjuvant + Adjuvant Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Intravenously, 85 mg/m2, over 2 hours, 2 cycles</description>
    <arm_group_label>Neoadjuvant + Adjuvant Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Microarray analysis</intervention_name>
    <description>Analysis of tumor for pathologic response to protocol therapy</description>
    <arm_group_label>Neoadjuvant + Adjuvant Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
    <description>Analysis of tumor for pathologic response to protocol therapy</description>
    <arm_group_label>Neoadjuvant + Adjuvant Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional surgery</intervention_name>
    <description>Surgical removal of tumor for correlative studies</description>
    <arm_group_label>Neoadjuvant + Adjuvant Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of adenocarcinoma of the esophagus meeting the following criteria:

               -  Stage II or III disease

               -  Resectable disease

               -  Previously untreated disease

          -  No stage I (mucosal only) or stage IV (metastatic) disease

        PATIENT CHARACTERISTICS:

          -  WBC &gt; 3,000/mm^3

          -  Absolute neutrophil count &gt; 1,500/mm^3

          -  Platelet count &gt; 100,000/mm^3

          -  Creatinine ≤ 2.0 mg/dL

          -  Bilirubin &lt; 2 times normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Must have central venous access

          -  No other malignancy within the past 5 years

          -  No concurrent medical or psychiatric problem that would preclude study treatment

          -  No contraindications to paclitaxel

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy or radiotherapy to the esophagus

          -  No oral cryotherapy (e.g., ice chips) on day 1 of each course
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bach Ardalan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami Sylvester Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Solomon N, Mezentsev D, Reis I, Lima M, Rios J, Avisar E, Franceschi D, Livingstone A, Podolsky L, Ardalan B. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma. Jpn J Clin Oncol. 2011 Apr;41(4):469-76. doi: 10.1093/jjco/hyq239. Epub 2011 Jan 21.</citation>
    <PMID>21258083</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2007</study_first_submitted>
  <study_first_submitted_qc>March 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2007</study_first_posted>
  <results_first_submitted>January 16, 2013</results_first_submitted>
  <results_first_submitted_qc>January 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 18, 2013</results_first_posted>
  <last_update_submitted>December 14, 2016</last_update_submitted>
  <last_update_submitted_qc>December 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Neoadjuvant + Adjuvant Chemotherapy</title>
          <description>Floxuridine : Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles
Leucovorin : Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles
Conventional surgery : Surgical removal of tumor for correlative studies
reverse transcriptase-polymerase chain reaction : Analysis of tumor for pathologic response to protocol therapy
Docetaxel : Intravenously, 25 mg/m2, over 30 minutes, 2 cycles
Microarray analysis : Analysis of tumor for pathologic response to protocol therapy
Oxaliplatin : Intravenously, 85 mg/m2, over 2 hours, 2 cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm</title>
          <description>5-Fluorodeoxyuridine, Leucovorin, Oxaliplatin and Docetaxel</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="50" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Complete Response</title>
        <description>No evidence of cellular residual cancerous cells as evidenced by tumor tissue samples taken via surgery at the end of neo-adjuvant chemotherapy.</description>
        <time_frame>8 - 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Floxuridine : Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles
Leucovorin : Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles
Conventional surgery : Surgical removal of tumor for correlative studies
reverse transcriptase-polymerase chain reaction : Analysis of tumor for pathologic response to protocol therapy
Docetaxel : Intravenously, 25 mg/m2, over 30 minutes, 2 cycles
Microarray analysis : Analysis of tumor for pathologic response to protocol therapy
Oxaliplatin : Intravenously, 85 mg/m2, over 2 hours, 2 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response</title>
          <description>No evidence of cellular residual cancerous cells as evidenced by tumor tissue samples taken via surgery at the end of neo-adjuvant chemotherapy.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="5.9" upper_limit="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response</title>
        <description>Overall response = Complete response (CR) + Partial Response (PR). Evaluated via endoscopic ultrasounds, PET and CT scans of the chest:
Complete Response (CR) applies to participants complete disappearance of all measurable and evaluable disease. No new lesion. No disease related symptoms. No evidence of non-evaluable disease, including tumor markers and other laboratory values.
Partial Response (PR) applies to participants with at least 50 percent reduction in the sum of the products of bi-dimensional perpendicular diameters of all measurable lesions. No progression of evaluable disease. No new lesions.</description>
        <time_frame>8 - 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Floxuridine : Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles
Leucovorin : Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles
Conventional surgery : Surgical removal of tumor for correlative studies
reverse transcriptase-polymerase chain reaction : Analysis of tumor for pathologic response to protocol therapy
Docetaxel : Intravenously, 25 mg/m2, over 30 minutes, 2 cycles
Microarray analysis : Analysis of tumor for pathologic response to protocol therapy
Oxaliplatin : Intravenously, 85 mg/m2, over 2 hours, 2 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response</title>
          <description>Overall response = Complete response (CR) + Partial Response (PR). Evaluated via endoscopic ultrasounds, PET and CT scans of the chest:
Complete Response (CR) applies to participants complete disappearance of all measurable and evaluable disease. No new lesion. No disease related symptoms. No evidence of non-evaluable disease, including tumor markers and other laboratory values.
Partial Response (PR) applies to participants with at least 50 percent reduction in the sum of the products of bi-dimensional perpendicular diameters of all measurable lesions. No progression of evaluable disease. No new lesions.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" lower_limit="55.7" upper_limit="85.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression-free Survival (PFS)</title>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Floxuridine : Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles
Leucovorin : Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles
Conventional surgery : Surgical removal of tumor for correlative studies
reverse transcriptase-polymerase chain reaction : Analysis of tumor for pathologic response to protocol therapy
Docetaxel : Intravenously, 25 mg/m2, over 30 minutes, 2 cycles
Microarray analysis : Analysis of tumor for pathologic response to protocol therapy
Oxaliplatin : Intravenously, 85 mg/m2, over 2 hours, 2 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-free Survival (PFS)</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="9" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Floxuridine : Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles
Leucovorin : Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles
Conventional surgery : Surgical removal of tumor for correlative studies
reverse transcriptase-polymerase chain reaction : Analysis of tumor for pathologic response to protocol therapy
Docetaxel : Intravenously, 25 mg/m2, over 30 minutes, 2 cycles
Microarray analysis : Analysis of tumor for pathologic response to protocol therapy
Oxaliplatin : Intravenously, 85 mg/m2, over 2 hours, 2 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="13.6" upper_limit="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Arm</title>
          <description>Floxuridine : Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles
Leucovorin : Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles
Conventional surgery : Surgical removal of tumor for correlative studies
reverse transcriptase-polymerase chain reaction : Analysis of tumor for pathologic response to protocol therapy
Docetaxel : Intravenously, 25 mg/m2, over 30 minutes, 2 cycles
Microarray analysis : Analysis of tumor for pathologic response to protocol therapy
Oxaliplatin : Intravenously, 85 mg/m2, over 2 hours, 2 cycles</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Grade 4 Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Grade 3 Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Grade 3Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Grade 3 Deep Venous Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Grade 3 Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bach Ardalan MD, Professor</name_or_title>
      <organization>UM/Sylvester Comprehensive Cancer Center</organization>
      <phone>305-243-4909</phone>
      <email>bardalan@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

